Despite warnings, American and European officials gave up leverage that could have guaranteed access for billions of people. That risks prolonging the pandemic.
While Washington went into business with the drug companies, Europe was more fiscally conservative and trusted the free market.
Shortages of shots for yellow fever, polio and other diseases have led to innovative solutions even in very poor countries.
As cases surge and hospital beds fill up, federal officials said a vaccine could be distributed to as many as 24 million people by mid-January.
With vaccines and a new administration, the pandemic will be tamed. But experts say the coming months “are going to be just horrible.”
Dr. Moncef Slaoui, the head of Operation Warp Speed, talks to Kara Swisher about a data-driven timeline, sticking to the science and battle rhythms.
Operation Warp Speed has moved along at a rapid clip. But some people involved in the approval process fear pressure to deliver an October surprise for President Trump.
Dr. Moncef Slaoui, the chief adviser for the Trump administration’s coronavirus vaccine program, can remain a government contractor, thus shielding him from disclosure rules.
The White House is eager to project progress, but the public-private partnership it has created still faces scientific hurdles, internal tensions and questions from Congress.
Moncef Slaoui, a former pharmaceutical executive, is now overseeing the U.S. initiative to development coronavirus treatments and vaccines. His financial interests and corporate roles have come under scrutiny.
Moncef Slaoui, a former pharmaceutical executive the White House chose to lead a crash development program, acknowledged that the 12-18 month timeline cited by Dr. Anthony Fauci was already “very aggressive.”
The chief operating officer will be an Army general who specializes in logistics.